Premium
Testosterone potentiated 32 P therapy in prostatic carcinoma
Author(s) -
Donati Robert M.,
Ellis Harry,
Gallagher Neil I.
Publication year - 1966
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196608)19:8<1088::aid-cncr2820190806>3.0.co;2-o
Subject(s) - medicine , testosterone (patch) , carcinoma , palliative treatment , palliative care , urology , metastatic carcinoma , cancer , palliative therapy , intractable pain , pain relief , surgery , oncology , nursing
Twelve patients with metastatic prostatic carcinoma and intractable bone pain were treated with testosterone potentiated 32 P therapy. One patient expired prior to the completion of therapy; in the remaining 11 patients there was marked relief of pain allowing the discontinuance of narcotics for an average period of 6.3 months. In 9 of the 11 patients radiographic improvement of osseous metastases was demonstrated. The authors conclude that testosterone potentiated 32 P therapy is a valuable adjunct in the palliative therapy of metastatic osseous prostatic cancer.